文献速递肺外科食管与纵隔外科

脓胸治疗现状

Current State of Empyema Management.
PubMed 文献 · Ann Thorac Surg · 2018-03-14

该研究利用纽约州住院患者数据库(2009至2014年)分析了4095例原发性脓胸患者的治疗方式与结局,比较胸管引流、电视辅助胸腔镜手术(VATS)剥脱引流和开放剥脱引流三组。结果显示胸管组初始住院死亡率、30天再入院率及再入院时再干预率均高于手术组,作者认为部分胸管治疗患者可能受益于更早的确定性手术干预。

要点

  • 胸管组初始住院死亡率为15.4%,高于VATS组的4.7%和开放组的6.0%(p < 0.001)。
  • 胸管组30天再入院率为7.3%,高于VATS组的3.8%和开放组的4.1%(p < 0.001)。
  • 再入院时再干预率胸管组为6.1%,高于VATS组的1.9%和开放组的2.1%(p < 0.001)。

核心结论

  • 胸管治疗患者的再入院率和再干预率较高,提示部分患者可能受益于更早的确定性手术干预。

研究设计与样本

  • 回顾性队列研究,查询医疗成本与利用项目纽约州住院患者数据库(2009至2014年),纳入4095例接受干预的原发性脓胸患者,按初始住院期间 definitive 治疗分为胸管引流组、VATS剥脱引流组和开放剥脱引流组。

主要发现

  • 大多数患者接受了确定性手术治疗:胸管组38.2%,VATS组32.1%,开放组29.8%(p < 0.001)。
  • 初始住院死亡率:胸管组15.4%,VATS组4.7%,开放组6.0%(p < 0.001)。
  • 30天再入院率:胸管组7.3%,VATS组3.8%,开放组4.1%(p < 0.001)。
  • 再入院时再干预率:胸管组6.1%,VATS组1.9%,开放组2.1%(p < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Empyema affects up to 65,000 patients annually in the United States. Recent consensus guidelines demonstrate ambiguity about optimal treatment. We examined current treatment practices and outcomes for inpatient treatment of empyema using a comprehensive, longitudinal data set that encompasses an entire state cohort of hospitalized patients. METHODS: We queried the Healthcare Cost and Utilization Project New York State Inpatient Database (2009 to 2014) for patients with primary empyema and subsequent readmissions. Patients were categorized into three groups by definitive treatment during their initial hospitalization: chest tube drainage, video-assisted thoracoscopic surgery (VATS) decortication and drainage, or open decortication and drainage. Treatment outcomes, including success rates, readmission, reintervention, and mortality, were compared between groups. RESULTS: The cohort included 4,095 patients undergoing intervention for primary empyema discharged during this period with chest tube, VATS, or open drainage and decortication. Most patients received definitive operative management (chest tube: 38.2%, VATS: 32.1%, open: 29.8%; p < 0.001). Patients had a high mortality rate during their initial hospitalization (chest tube: 15.4%, VATS: 4.7%, open: 6.0%; p < 0.001) and a substantial 30-day readmission rate for empyema (chest tube: 7.3%, VATS: 3.8%, open: 4.1%; p < 0.001), with reintervention at readmission significantly higher for chest tube (6.1%) vs surgical patients (VATS: 1.9%, open 2.1%; p < 0.001). CONCLUSIONS: This study characterizes recent treatment practices of patients with empyema. Higher readmission and reintervention rates were observed in patients managed with chest tubes, suggesting some of these patients may benefit from earlier definitive surgical intervention.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Semenkovich TR, Olsen MA, Puri V, et al. Current State of Empyema Management. Ann Thorac Surg. 2018. PMID: 29550205. doi:10.1016/j.athoracsur.2018.02.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。